Member Info for stephen11

All the companies below have large American divisions - take your pick.

James Cheek has previously worked for three of the worlds leading diagnostic companies. That is:

Cepheid - Revenue for 2022 - $4.3 Billion

Beckman Coulter - Revenue for 2022 - $4.7 Billion

Roache Diagnostics Division - Revenue for 2022 - $17.7 Billion

In roles within these companies he had extensive involvement in selling directly to the NHS. Additionally, his experience from being a Director of the British In Vitro Diagnostic Association (BIVDA) should prove invaluable, given this organisations close working relationships and previous collaborations with the NHS.

GLA.

Stephen11.

Can i just echo the valid point about AIM share prices being driven by sentiment - two examples below:

- May 5th 2020: GDRs SP was £2.19 (on the rumour of the COVID test - the government opted for inferior Chinese tests, but that's another story)

- Feb 12th May 2021: GDRs SP was £1.48 (on the back of the Beckman Coulter deal and FDA application for the COVID test, although unfortunately the Americans preferred their own tests).

The difference now is we have world firsts, in the AHIL and Stroke tests operating in a much less saturated market place.

The future is bright.

Stephen11.

Https://ndau-maps.github.io/UnitMap2020/

Here is a map of all the neonatal units in the UK. Wouldn’t it be great to have an MTRNR1 test machine in each location.

It will happen through commissioning some day 😊.

GLA.

Stephen11.

Let's not forget that the MTRNR1 test can and has saved children from lifelong hearing loss as it prevents adverse drug reactions from certain medications that premature babies may require. The test allows for an alternative and more suitable medication to be administered within a speedy, yet critical time frame. It's also the only test of its kind in the world.

I'm thinking that irrespective of full NICE accreditation we may see a type of de-facto adoption when between 5 and 10 NHS Trusts acquire the test around the UK.

Let's think about this!?

If Manchester, Brighton, Edinburgh, and Belfast Trusts were saving children from lifelong hearing loss it would be extremely unfair if premature babies from neighboring Trusts (Liverpool, Kent, Glasgow, or Craigavon) didn't have access to the same test. In this sense after a certain amount of adoption and success, the test should sell itself.

GLA.

Stephen11

Interesting conversation thread this morning, but to add balance, take note of what James Cheek said about the specialist commissioning of the MTRNR1 Test - the "100% clarity its happening" comment in particular.

From 23 minutes onwards in the GDR investormeetcompany presentation James Cheek is speaking about early adoption of the MTRNR1 hearing loss test through the NHS Special Commissioning programme.

He states "Pretty much got absolute 100% clarity that it is happening...big driver is to make sure it happens as quickly as possible." For the cynics amongst you, please listen to the presentation.

What is Special Commissioning? (info taken from NHS website)

- Special Commissioning is used to ensure smaller population have access to adequate medical provision to meet their specific needs. The population size can be as low as a few thousand or as many as 100,000

* Massive tick for GDR as there are 60,000 premature babies born in the UK per year

- Certain cohorts of the products and populations are prioritised for special commissioning. These include babies, infants, and children

* Massive tick for GDR

- The NHS 2022/23 budget for special commissioning was 22.9 billion and is increasing in 2023/23

* Massive tick for GDR

In a de facto manner Special Commissioning could be as good as full NICE accreditation.

GLA.

Stephen11.

Are you still holding Punit?

Said the priest to the alter boy - couldn’t resist a bit of adolescent humour 😂.

I was thinking the same bigAl67 - and we also have a tax credit due in Q1 - cash runway is in good shape for a while yet 😊

Thanks bigAl67 👍 - and the same to you. Lots to be happy about in 2024 😊

The 600,000 drawdown.

This would indicate a placing is not imminent, as some would suggest.

Yes, money will be required at some stage for FDA submission, though it might not be in the month of January.

News due on multiple fronts so it could prove to be a very exciting month.

GLA.

Stephen11.

Wait till we start to get drill results on the gold, more lithium drill results, and updates on the plant - 2024 should be a blinder.

In context - Kodal own gold resources that are approximately 3 times the size of the Isle of man!

Detailed breakdown below:

Names and numbers for the Gold concessions in Cote d'Ivoire and Corvette

Corvette:

PR-399 212 Km² (NIELLE)

PR400 396.761 Km² (M’BIHIAKRO)

PR-398 229.02 Km² (TIEBISSOU)

International Goldfields Cote d’Ivoire

PR0834 394.7647Km² (BOUNDIALI)

PR-427 200.4052Km² (KORHOGO)

PR-426 220.7688 Km² (DABAKALA)

Obviously, i would presume the gold will not be evenly distributed amongst this land and the ongoing testing will be needed to identify the best ground - but its vast!

GLA.

Stephen11.

Come on James!…give us another Cheeky RNS before then to spread some cheer as we approach the New Year 🤞.

GLA.

Stephen11.

Have you been smoking the funny cigarettes over Christmas TIA1?

I am quietly optimistic that 2024 will be a dramatically better year for GDR.

These types of stocks can be marred by lengthy testing and validation, as has happened with GDR.

The difference is we now have a CEO in place with a proven track record in the sales and commercialisation of pharmocogenic devices. News due on multiple front between now and the end of January.

All stocks are a risk, but this stock is a diamond in the rough, and a risk I am happy live with.

Happy Christmas and New Year to all.

Stephen11.

Well said Raffs60

Thanks bigAl67 - have a great Christmas and New Year.

Thanks bigAl67,

Yes, it was a good question you raised about the 1.2m....strange we are not getting the full amount!

If it was me i would concentrate on selling the two world beating products that we have and reduce the R+D costs by putting new products on hold for a while until we get commercial traction. I too thought Shaw was eluding to this in March 2023 - was a figure of £275, 000 per month not muted from memory?

All the best,

Stephen11.

Thanks Tiddlerontheroof and bigAl67.

Hope your keeping well bigAl67,

Could i ask a favour? When your schedule permits could you post a little synopsis of GDRs current cash position?...you always have an accurate gauge over the figures. Its just i was was seeing a lot of misinformation being posted earlier, by Starresnstoff and the likes.

GLA.

Stephen11.

Continued - Part 2

**Stroke Test - CYP2CI9**

- The CYP2CI9 test is being actively marketed around Europe as a research only product - to create interest around the various countries and to create early commercial traction

- A US peer reviewed study has shown that hospitilisation from an adverse reaction to Clipidogrel costs on average $8 to $20 thousand dollars per person - the CYP2CI9 test would eradicate this cost

**The Future - Near Term**

- Revenue and commercial traction for the hearing loss test imminent - as soon as Dec this year and Jan next year

- 100% clarity from the new CEO that special commissioning for the hearing loss test will happen

- Contracts being drawn up with potential partners who can help with the FDA application for the hearing loss product in a cost effective manner

- NICE full validation for the MTRNR1 is being hindered by the EVO procedure and not the product - news due Jan 2024

- NICE Review of the CYP2CI9 - due Jan 2024

- Funding: early 2024 fundraise will be specifically for FDA of the MTRNR1 - RF drawdowns, sales, and tax credits will cover the monthly cash burn, despite what the derampers say!

- More grant funding is also a possibility e.g., through MedTech etc.

**The Future - Long Term**

- European registration of CYP2CI9

- FDA registration of MTRNR1

**Conclusion**

------------------Strong Buy and hold all day long--------------

GLA.

Stephen11.

Part 1 of 2

I was extremely impressed with the new CEO, his strategies for commercialisation, and his vision for the company. Here's why:

**Introduction**

- James brings a significant level of commercial and diagnostic experience gleaned from 20 years with Roache, Beckman Coulter, and Cepheid

- He has previously worked at board level in BIDVA where he gained specialist knowledge in NHS supply chain management and procurement procedures - experience which will prove invaluable to GDR

- He was brought in to increase sales and his main remit from the board of GDR is to generate commercial traction ASAP

- The company intends to focus solely on pharmacogenetics i.e., specifically in the prevention of the prescription of drugs that produce Adverse Drug Reactions (ADRs) because the infectious diseases market is over saturated at present

- ADRs cost the NHS £2.2B in extra hospital days per year. Overall, pharmacogenetics testing could effect 30% of these cases, which in terms of health economics could save the NHS £660m per year

**Hearing Loss (AHIL) - MT-RNR1**

- The MT-RNR1 test has no known competitors at present

- The Total Addressable Market value is around £100M: UK £8.5M / EU £46.75M / US £34M / ROW £13.75M

- Last month software and training materials for the MT-RNR1 test were translated into several foreign languages (this had not been the case under David Budd's tenure). James Cheek reported that he expected to see orders coming in from European countries in the month of December 2023

- James is actively speaking to those in charge of NHS budgets in regards to getting the MT-RNR1 test commissioned nationally in the UK

- JC is speaking to regional innovation networks (e.g., in Scotland and Wales) and various health trusts to gain commercial traction in Dec 23 and Jan 24 (The Royal Sussex County Hospital, Brighton has been announced on RNS today)

- In discussions the FDA have been incredible supportive about the MT-RNR1 test and JC reported that a deal with an American partner could be announced Dec 23 or Jan 24

- Financial modelling for the hearing loss test now considers the wider social economic cost of raising a child with hearing loss

- The test also provides information on adverse drug reactions for the mother, grandmother, and siblings

**Stroke Test - CYP2CI9**

- GDR has a competitor in the market, however this is not a proper point of care test, has a longer test time, and has limited capabilities compared with the CYP2C19 test

- The Total Addressable Market is around £220M: UK £8.5M / EU £93.5M / US £67.58M / ROI 51M

- The Manchester Health Trust will be starting to use this product routinely in late Dec 23 or early Jan 24

- GDR are actively speaking to other health trusts around the UK and have garnered a considerable amount of interest

****